Avian and Swine Flu News ArticlesExcerpts of Key Avian and Swine Flu News Articles in Media
Scientists agreed not to publish certain details of research showing how lethal bird flu can be made contagious after a U.S. biosecurity panel asked that it be kept secret for security reasons. The study at Erasmus Medical Center in Rotterdam described the genetic changes needed to make the H5N1 avian influenza strain spread easily among ferrets and potentially people. The research is under review for publication in the journal Science. It was commissioned by the U.S. National Institutes of Health, the center said yesterday in a statement on its website. Knowing the genetic sequence of a deadly, infectious strain may enable the virus to be recreated through reverse engineering. The censorship was requested by the National Science Advisory Board for Biosecurity, which was created in the aftermath of the 2001 anthrax attacks and advises the U.S. Department of Health and Human Services. The panel called for certain data to be kept secret after determining that the risks of publishing it outweigh the benefits, the Erasmus Medical Center said. “The researchers have reservations about this recommendation but will observe it,” the center said in the statement.
Note: For key major media reports revealing manipulation around both the avian and swine flus, click here. For solid evidence that Lyme disease originated in a secret government germ laboratory, click here.
Attempts to censor details of controversial influenza experiments that created a highly infectious form of bird-flu virus are unlikely to stop the information from leaking out, according to scientists familiar with the research. The US Government has asked the editors of two scientific journals to refrain from publishing key parts of research on the H5N1 strain of bird-flu in order to prevent the information falling into the hands of terrorists intent on recreating the same flu strain for use as a bioweapon. However, scientists yesterday condemned the move. Some said that the decision comes too late because the information has already been shared widely among flu researchers, while others argued that the move could obstruct attempts to find new vaccines and drugs against an infectious form of human H5N1 if it appeared naturally. Professor Richard Ebright, a molecular biologist at Rutgers University in Piscataway, New Jersey, said that the research, which was funded by the US Government, should never have been done without first assessing the risks and benefits. “The work posed risks that outweighed benefits and that were clearly foreseeable before the work was performed,” Professor Ebright said. “The work should have been reviewed at the national or international level before being performed, and should have been restricted at a national or international level before being performed,” he said.
Note: For key major media reports revealing manipulation around both the avian and swine flus, click here. For solid evidence that Lyme disease originated in a secret government germ laboratory, click here.
A leading health expert says the swine flu scare was a "false pandemic" led by drugs companies that stood to make billions from vaccines. Wolfgang Wodarg, head of health at the Council of Europe, claims major [drug] firms organised a "campaign of panic" to put pressure on the World Health Organisation to declare a pandemic. He believes it is "one of the greatest medicine scandals of the century" — and has called for an inquiry. Dr Wodarg said: "It's just a normal kind of flu. It does not cause a tenth of deaths caused by the classic seasonal flu. The great campaign of panic we have seen provided a golden opportunity for representatives from labs who knew they would hit the jackpot in the case of a pandemic being declared. We want to clarify everything that brought about this massive operation of disinformation. We want to know who made decisions, on the basis of what evidence, and precisely how the influence of the pharmaceutical industry came to bear on the decision-making." He added: "A group of people in the WHO is associated very closely with the pharmaceutical industry."
Note: For powerfully revealing reports of the corruption regarding swine flu and previous health scares, click here.
A new analysis, using H1N1 deaths in the United States in the spring and projecting likely outcomes for this fall, shows that a typical -- or possibly even a milder flu season than average -- should have been expected. The finding [raises] the question: Has swine flu been oversold? The new study, done by researchers at Harvard University and the Medical Research Council Biostatistics Unit in the U.K., says swine flu cases in the spring indicated a flu season that might be, at worst, slightly worse than normal. "It would have been great to have that back in June," said Philip Alcabes, an associate professor in the program in urban public health at Hunter College's School of Health Sciences. "There would have been one more bit of evidence behind my assertion six months ago" that people were overreacting to H1N1. Around the time that swine flu first started making headlines, Alcabes' book, Dread: How Fear and Fantasy Have Fueled Epidemics From the Black Death to Avian Flu, was published, and he said the circumstances surrounding H1N1 provide an apt case study. "I think that it was, from the very beginning, created as a crisis and overstated as a real threat," he said.
Swiss drugmaker Novartis said sales would grow faster than expected this year, even without a shot in the arm of up to $700 million from its H1N1 swine flu pandemic vaccine. Third-quarter net profit at Novartis ... nudged up 1 percent to $2.1 billion. This year is turning out to be better than initially feared for Novartis and other major pharmaceutical companies, thanks to hefty price increases and windfall sales arising from the H1N1 outbreak. Both Pfizer, the world's biggest drugmaker, and Eli Lilly topped earnings forecasts this week. Roche reported a sharp jump in sales of its Tamiflu drug for flu last week and analysts expect GlaxoSmithKline's Relenza will also see strong sales in the third quarter. On the vaccine front, Glaxo, Sanofi-Aventis and AstraZeneca are all expected to highlight an expected jump in fourth-quarter sales due to swine flu. The H1N1 flu vaccine is expected to contribute about $400-700 million of sales in the fourth quarter.
Note: Donald Rumsfeld personally made millions as a direct result of the avian flu scare a few year ago. For more on this, click here. For more on pharmaceutical corporation profiteering from swine flu vaccines, click here.
U.S. military troops will begin getting required swine flu shots in the next week to 10 days, with active duty forces deploying to war zones and other critical areas going to the front of the vaccine line. Air Force Gen. Gene Renuart also [said] that as many as 400 troops are ready to go to five regional headquarters around the country to assist federal health and emergency management officials. The Pentagon has bought 2.7 million vaccines, and 1.4 million of those will go to active duty military. National Guard troops on active duty are also required to receive the vaccine, as are civilian Defense Department employees who are in critical jobs. "Because I can compel people to get the shots, larger numbers will have the vaccine," said Renuart, commander of U.S. Northern Command. "They will, as a percentage of the population, be vaccinated more rapidly than many of us. So we may see some objective results, good or not, of the vaccinations." Shots will be doled out on a priority basis, with troops preparing to deploy first, followed by other active duty forces, particularly any who might be needed to quickly respond to a hurricane or other emergency. Inoculating the military is a key requirement of the Pentagon's emergency plan, as a way to ensure that troops are available to protect the nation. They also will be on tap to provide help to states if problems come up as the flu season continues.
Note: It is not made clear by this article precisely how military personnel will "assist" civilian authorities handle a mass swine flue vaccination program. The plans to use the military for this purpose are unprecedented and formerly illegal. For lots more from reliable sources on the dangers of vaccines, click here and here.
The nation's political crosscurrents appear to have created vaccine skeptics of many stripes. Many citizens are less inclined than ever to accept the warnings of the Department of Health and Human Services or the recommendations of its Centers for Disease Control and Prevention, says Sandra Quinn, a University of Pittsburgh public health professor who has just completed a national survey of attitudes about the flu vaccine. Vaccine refusers have long decried vaccine mandates and campaigns as an unwarranted intrusion of parents' and local school boards' rights. For a new generation of vaccine skeptics, there are new objects of distrust. For some, it flows from a suspicion of the multinational corporations that develop and manufacture vaccines. For others, it comes from a belief that media outlets have hyped the pandemic flu story to secure the attention of readers and the revenue of advertisers. And many simply doubt the competency and independence of government agencies, which they believe are too inept, overwhelmed or co-opted by corporate interests to secure the safety of the nation's drugs and food supply. Adding to the wariness toward the forthcoming H1N1 vaccine is the fact that the formulations used on patients in the United States might require the use of adjuvants -- special agents added to a vaccine mix that rev up the immune system and foster a stronger immune response. While adjuvants have been used in vaccines in Europe for many years, the FDA has never approved them for widespread use in the United States. Some vaccine critics in Great Britain have charged that one adjuvant used in European formulations -- squalene -- is associated with a wide range of vague but persistent symptoms.
Note: Adjuvants are being added to vaccines, yet the resulting combined formula is not being tested for safety; the individual components are tested separately. The process for the testing of vaccines is endangering our health. For lots more on the dangers of vaccines and squalene in particular, read respected Dr. Joseph Mercola's incisive article available here.
U.S. government health officials are urging Americans not to panic over estimates that up to 90,000 people might die in the United States from swine flu this year. "Everything we've seen in the U.S. and everything we've seen around the world suggests we won't see that kind of number if the virus doesn't change," said Dr. Thomas Frieden, head of the Centers for Disease Control and Prevention. While the swine flu seems quite easy to catch, it so far hasn't been more deadly than the flu strains seen every fall and winter — many people have only mild illness. And close genetic tracking of the new virus as it circled the globe over the last five months so far has shown no sign that it's mutating to become more virulent. Still, the CDC has been preparing for a worst-case flu season as a precaution — in July working from an estimate slightly more grim than one that made headlines this week — to make sure that if the virus suddenly worsened or vaccination plans fell through, health authorities would know how to react. On Monday the White House released a report from a group of presidential advisers that included a scenario where anywhere from 30 percent to half of the population could catch what doctors call the "2009 H1N1" flu, and death possibilities ranged from 30,000 to 90,000. "We don't think that's the most likely scenario," CDC flu specialist Dr. Anne Schuchat said of the presidential advisers' high-end tally. In a regular flu season, up to 20 per cent of the population is infected and 36,000 die.
Note: Like the avian flu several years ago, the swine flu is turning out to be largely fear-mongering which has poured billions of dollars into the deep pockets of the medical/industrial complex. For lots more reliable information from major media reports on this, click here.
Many GPs, as well as their patients, may be reluctant to be immunised against swine flu once a vaccine is developed, surveys suggest today. A survey of GPs published on Healthcare Republic, the website of GP magazine, found that up to 60% of GPs may decline vaccination. Although the numbers who responded were small – 216 GPs – they are in line with a much bigger survey of nurses published a week ago by Nursing Times, which found that a third of 1,500 nurses would refuse vaccination. A Canadian study published today in the journal Emerging Health Threats suggests the public, too, will have reservations that must be overcome if a vaccination campaign is to be successful in the autumn or winter. The study, which used focus groups to establish the likely response of different people to a vaccine, pointed to the need to win over people who believe that alternative therapies and a good diet are a better option than vaccines. But the biggest problem in persuading people and healthcare professionals to have the jab may be the relative shortage of evidence from trials about its safety and efficacy. Because of the urgent need for a vaccine, testing will be limited. Among the GPs who responded to the survey published by Healthcare Republic, 29% said they would not choose to have the vaccine and 29% said they were unsure whether or not they would. The biggest reason given by those who said they would not have it was concern that the safety trials would not be adequate: 71.3% said they were "concerned that the vaccine has not yet been through sufficient trials to guarantee safety". Half – 50.4% – said they "believe that swine flu is too mild to justify taking the vaccine".
Note: Yet the Massachusetts Senate has now passed a bill which would impose fines up to $1,000 and jail up to 30 days for those who refuse vaccines or quarantine orders in a health emergency. Other states are considering similar legislation. For lots more on the real dangers of the swine flu vaccine, click here.
The flu drugs Tamiflu and Relenza may not be worthwhile to treat seasonal influenza in healthy adults, British researchers reported on Friday. "Recommending the use of antiviral drugs for the treatment of people presenting with symptoms is unlikely to be the most appropriate course of action," wrote Jane Burch of the University of York and colleagues. Their study, published in the Lancet Infectious Diseases, supports an advisory from the World Health Organization that says healthy patients who get H1N1 swine flu without suffering complications do not need to be treated with antivirals. Burch's team reviewed many different published studies on Tamiflu and Relenza. "We present the results for healthy adults and people at-risk of influenza-related complications," they wrote. Both drugs shaved about half a day, on average, off the time patients were ill, they found. Influenza usually affects people for about a week. The drugs worked a little better in people who have a high risk of complications, such as patients with diabetes or asthma, with Relenza cutting sickness by almost a day and Tamiflu by three-quarters of a day, on average. This suggests the drugs should be reserved for people who need them the most, the researchers concluded.
Note: To read a powerful account of the real dangers of the swine flu scare, click here.
A warning that the new swine flu jab is linked to a deadly nerve disease has been sent by the Government to senior neurologists in a confidential letter. The letter from the Health Protection Agency, the official body that oversees public health, has been leaked to The Mail on Sunday, leading to demands to know why the information has not been given to the public before the vaccination of millions of people, including children, begins. [The letter] tells the neurologists that they must be alert for an increase in a brain disorder called Guillain-Barre Syndrome (GBS), which could be triggered by the vaccine. GBS attacks the lining of the nerves, causing paralysis and inability to breathe, and can be fatal. The letter, sent to about 600 neurologists on July 29, is the first sign that there is concern at the highest levels that the vaccine itself could cause serious complications. It refers to the use of a similar swine flu vaccine in the United States in 1976 when: * More people died from the vaccination than from swine flu. * 500 cases of GBS were detected. * The vaccine may have increased the risk of contracting GBS by eight times. * The vaccine was withdrawn after just ten weeks when the link with GBS became clear. * The US Government was forced to pay out millions of dollars to those affected. Concerns have already been raised that the new vaccine has not been sufficiently tested and that the effects, especially on children, are unknown. The British Neurological Surveillance Unit (BNSU), part of the British Association of Neurologists, has been asked to monitor closely any cases of GBS as the vaccine is rolled out. One senior neurologist said last night: ‘I would not have the swine flu jab because of the GBS risk.’
Note: For more on the swine flu scare and the dangers of vaccines, click here.
A complicated list of who should get [swine] flu vaccine in the fall is now set. When the vaccine starts arriving in September, first in line will be pregnant women; the caretakers of infants; children and young adults; older people with chronic illness; and health-care workers. That's the advice of a 15-member committee of experts, which met all day Wednesday at the Centers for Disease Control and Prevention in Atlanta to advise the federal government on vaccine policy. The priority list names targeted groups and suggests the order in which they should be vaccinated. "The results of this meeting will kick planning into high gear," said Pascale Wortley of the CDC's Immunization Services Division. "This is a watershed moment." All that's missing is the vaccine, knowledge of how well it works and the nitty-gritty details of how to deliver it to people's arms and noses. The vaccine will come in two forms: the traditional flu shot and a "live" vaccine squirted into the nose that contains a weakened version of the new virus. Some of the vaccine will be stored in multi-dose vials containing thimerosal, an antibacterial additive that contains mercury. But there will also be single-dose syringes without thimerosal, a substance that some assert is harmful to children. Among the many unanswered questions is whether two doses will be necessary to provide full protection, how close in time two shots can be given and how big the dose will be. Vaccination programs may start before the answers are known.
Note: Why is thimerosal being used? It is a mercury additive around which there appears to be a major cover-up. For several other revealing articles which suggest an dangerous agenda with the swine flu vaccine, click here.
The last time the government embarked on a major vaccine campaign against a new swine flu, thousands filed claims contending they suffered side effects from the shots. This time, the government has already taken steps to head that off. Vaccine makers and federal officials will be immune from lawsuits that result from any new swine flu vaccine, under a document signed by Secretary of Health and Human Services Kathleen Sebelius, government health officials said Friday. Since the 1980s, the government has protected vaccine makers against lawsuits over the use of childhood vaccines. The document signed by Sebelius last month grants immunity to those making a swine flu vaccine, under the provisions of a 2006 law for public health emergencies. It allows for a compensation fund, if needed. The government takes such steps to encourage drug companies to make vaccines, and it's worked. Federal officials have contracted with five manufacturers to make a swine flu vaccine. The last time the government faced a new swine flu virus was in 1976. Federal officials vaccinated 40 million Americans during a national campaign. A pandemic never materialized, but thousands who got the shots filed injury claims, saying they suffered a paralyzing condition called Guillain-Barre Syndrome or other side effects.
Note: Note for a powerfully revealing CBS report on blatant fear mongering and profiteering from the 1976 swine flue scare, click here. For many revealing reports on corruption in the medical/governmental complex, click here.
A swelling number of scientists believe swine flu has not happened by accident. No: they argue that [it] is the direct result of our demand for cheap meat. So is the way we produce our food really making us sick as a pig? The scientific evidence increasingly suggests that we have unwittingly invented an artificial way to accelerate the evolution of these deadly viruses – and pump them out across the world. They are called factory farms. They manufacture low-cost flesh, with a side-dish of viruses to go. In most swine farms today, 6,000 pigs are crammed snout-to-snout in tiny cages where they can barely move, and are fed for life on an artificial pulp, while living on top of cess-pools of their own stale faeces. The virus ... has a pool of thousands [of pigs], constantly infecting and reinfecting each other. The virus can combine and recombine again and again. The ammonium from the waste they live above burns the pigs' respiratory tracts, making it easier yet for viruses to enter them. Better still, the pigs' immune systems are in free-fall. They are stressed, depressed, and permanently in panic, making them far easier to infect. There is no fresh air or sunlight to bolster their natural powers of resistance. They live in air thick with viral loads, and they are exposed every time they breathe in. As Dr Michael Greger, director of Public Health and Animal Agriculture at the Humane Society of the United States, explains: "Put all this together, and you have a perfect storm environment for these super-strains. If you wanted to create global pandemics, you'd build as many of these factory farms as possible."
Note: For many important reports on health issues from reliable sources, click here.
Pharmaceutical stocks are skyrocketing on fears that a swine flu outbreak could go global. Manufacturers of antiviral drugs [and] companies gearing up to produce a vaccine ... are turning profits in an otherwise skittish and down market. Companies gearing up for swine flu, including Roche, Gilead Sciences and GlaxoSmithKline, the manufacturers of the leading antiviral flu medications, are best positioned to see a boost in profits if the disease escalates to epidemic proportions, analysts said. Tamiflu ... was developed by Gilead and manufactured by Roche. Both companies' share prices spiked soon after the U.S. government allowed for its stockpiles of the drug to be made publicly available. Gilead stock surged to $47.53 at the end of the day Monday, up 3.78 percent. Roche rose to $31.72, up 4.34 percent. The other major flu drug currently on the market is Relenza, also stockpiled and released by the government, and manufactured by GlaxoSmithKline. Shares of Glaxo closed surged Monday to $31.56, up 7.57 percent. Both Tamiflu and Relenza are stockpiled by governments and in the case of an outbreak the companies are often required to sell the drugs directly to the government at a discount. "Government stockpiling is viewed as boon for profits. Though the government gets a discount and the margins sold to the government are lower than those if they sold to Walgreens, from a stock perspective it's an unexpected positive surprise," he said.
Note: Pharmaceutical companies make big bucks from scares like the avian flu and swine flu. Yet are the recommended drugs really effective? Many studies say they are not. For analysis of profiteering by the pharmaceutical industry during a previous flu scare, click here. See this link for lots more.
Using technology originally developed for mass disasters, Boston disease trackers are embarking on a novel experiment - one of the first in the country - aimed at eventually creating a citywide registry of everyone who has had a flu vaccination. The resulting vaccination map would allow swift intervention in neighborhoods left vulnerable to the fast-moving respiratory illness. The trial starts this afternoon, when several hundred people are expected to queue up for immunizations at the headquarters of the Boston Public Health Commission. Each of them will get a bracelet printed with a unique identifier code. Information about the vaccine's recipients, and the shot, will be entered into handheld devices similar to those used by delivery truck drivers. Infectious disease specialists in Boston and elsewhere predicted that the registry approach could prove even more useful if something more sinister strikes: a bioterrorism attack or the long-feared arrival of a global flu epidemic. In such crises, the registry could be used to track who received a special vaccine or antidote to a deadly germ. "Anything you can do to better pinpoint who's vaccinated and who's not, that's absolutely vital," said Michael Osterholm, director of the Center for Infectious Disease Research & Policy at the University of Minnesota. "I wish more cities were doing this kind of thing." When people arrive for their shots, they will get an ID bracelet with a barcode. Next, basic information - name, age, gender, address - will be entered into the patient tracking database. There will be electronic records, too, of who gave the vaccine and whether it was injected into the right arm or the left, and time-stamped for that day.
Japanese health authorities are investigating a flu medicine that is also available in Australia after a teenager jumped 11 storeys to his death after taking the drug. It was the 18th juvenile fatality linked to Tamiflu in 17 months. The Ministry of Health, Labour and Welfare has asked the Japanese importer of Tamiflu, an anti-viral drug regarded as the most important shield against bird flu in humans, to collect information about the conditions of patients who take the drug. The 14-year-old boy's death follows a similar case two weeks ago, when a girl also 14, died after jumping from an apartment building at Gamagori, in central Japan. It also comes after a warning by the US Food and Drug Administration late last year about the dangers of giving children Tamiflu. The drug is being stockpiled in Australia as the first line of defence against bird flu. In Australia, as in Japan, it is only available by prescription. Drug companies reported that 54 people using Tamiflu died in Japan before November, the ministry said.
Note: Tamiflu is the vaccine on which Donald Rumsfeld profited $5 million and on which the U.S. government has spent hundreds of millions of dollars stockpiling, even though it might not work. For more, click here.
Ministers are preparing to offload millions of unwanted swine flu vaccines, it has emerged, as officials predicted that there will be no third wave of the pandemic this winter. Millions of [dollars] could be wasted if the Government is unable to get out of orders for the vaccine it has placed with GlaxoSmithKline (GSK), the pharmaceutical giant. Officials confirmed that they are considering a number of options, including attempting to sell or give away millions of the vaccines. They also considering whether to stand down the National Pandemic Flu Service, the network of call centres which diagnose swine flu and hand out antiviral medications. In May, even before a pandemic had been declared, ministers had signed contracts thought to be worth around Ł100 million to deliver 90 million vaccines to Britain. Britain has now received almost 29 million doses of the H1N1 vaccine, but only just over 3.7 million have been given out and in total the Government has announced plans to inoculate only 14 million people.
Note: For a powerful insight into the corrupt symbiosis between pharmaceutical corporations and government, read this analysis by Marcia Angell, former editor of the New England Journal of Medicine. For lots more on the swine flu scare, click here.
As the pandemic H1N1 influenza surges with the onset of winter, the nations of Eastern Europe and the former Soviet Union appear particularly vulnerable to the deadly virus. Burdened with weak health-care systems, relatively inexperienced news media outlets and shaky governments that have little public trust, the region also seems ripe for panic and political strife over the flu. The potential for trouble is already on display in Ukraine, where 1.5 million of its 46 million people have had diagnoses of flu and respiratory illnesses since the start of the outbreak and 356 have died, according to the government. More telling than the numbers, however, has been the widespread fear the virus has caused in Ukraine, and the outsize impact it has had on the nation's political landscape. Anxious residents have overwhelmed hospitals and pharmacies, buying up supplies of medicine, gauze masks and home remedies such as lemons and garlic. Rumors have proliferated that people are dying of a new, more lethal strain of the virus. Semyon Gluzman, a psychiatrist and Soviet-era dissident in Kiev, said the fear was a rational response in a nation with a dysfunctional health-care system and a corrupt, ineffective government. "What we're seeing is a normal, psychological reaction to the complete incompetence of the state authorities," he said. "People are scared, and they don't know who to trust anymore."
With the U.S. Centers for Disease Control and Prevention hoping to have 120 million doses of H1N1 swine flu virus vaccine ready before flu season this fall, some are raising concerns over what they see as an effort to rush the drug through safety trials. The source of many of these concerns is the probability that the mercury-containing preservative thimerosal will be an ingredient in some of the doses of the new vaccine. Concern over thimerosal has lingered for years. Groups opposed to current vaccination practices continue to condemn thimerosal as a toxin responsible for the development of autism and related ailments in children. Additionally, the possibility that the swine flu vaccine could also contain an adjuvant, an ingredient that would allow more doses to be created from existing supplies of the vaccine, has also worried these groups. "We don't have adequate safety studies on this vaccine before we are moving forward to market," said Lyn Redwood, president and co-founder of the group SafeMinds. "I'm really not convinced that we know for sure that the risk of the disease outweighs the risk of the vaccine, especially since this is a brand new additive that we have never used before in combination with thimerosal." During the 1976-77 flu season, a vaccine developed to prevent the spread of a strain of the swine flu was linked to an as-yet-unexplained increase in cases of a rare neurological condition known as Guillain-Barre syndrome in those who received immunizations.
Note: For many powerful reports from reliable sources on the dangers of vaccines, click here.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.